Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citchem A is an oral fixed-dose combination tablet containing the antihistamine levocetirizine, the mucolytic agent ambroxol, and the nasal decongestant phenylephrine. Developed by Ultrachem Pharmaceuticals, this combination is indicated for the symptomatic relief of productive cough, nasal congestion, and allergic symptoms associated with the common cold, influenza, sinusitis, and allergic rhinitis. Levocetirizine acts as a selective, second-generation histamine H1 receptor antagonist to reduce allergic symptoms such as sneezing, rhinorrhea, and watery eyes. Ambroxol acts as a mucolytic that thins and loosens thick bronchial secretions, facilitating expectoration. Phenylephrine is a selective alpha-1 adrenergic receptor agonist that induces vasoconstriction in the nasal mucosa, thereby reducing nasal swelling and congestion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ambroxol + levocetirizine + phenylephrine.